By repurposing a typical dopamine D1/D5 receptor agonist motif, C1-substituted-N 3- benzazepine or benzazecine, into the classical RTK inhibitor 2, 4-diaminopyrimidine skeleton, a series of new 2, 4-diarylaminopyrimidine analogues (DAAPalogues) were developed. Compounds 7 and 8a were identified possessing high potency against both c- Met and ALK kinases. Compound 8a displayed appreciable antitumor efficacy at the dose ...